Liquid biopsy enters the clinic—implementation issues and future challenges
M Ignatiadis, GW Sledge, SS Jeffrey - Nature reviews Clinical oncology, 2021 - nature.com
Historically, studies of disseminated tumour cells in bone marrow and circulating tumour
cells in peripheral blood have provided crucial insights into cancer biology and the …
cells in peripheral blood have provided crucial insights into cancer biology and the …
[HTML][HTML] Liquid biopsy for advanced NSCLC: a consensus statement from the international association for the study of lung cancer
Although precision medicine has had a mixed impact on the clinical management of patients
with advanced-stage cancer overall, for NSCLC, and more specifically for lung …
with advanced-stage cancer overall, for NSCLC, and more specifically for lung …
Prediction of risk for myeloid malignancy in clonal hematopoiesis
Background Clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of
undetermined significance (CCUS) are defined by somatic mutations in genes associated …
undetermined significance (CCUS) are defined by somatic mutations in genes associated …
[HTML][HTML] Evaluation of cell-free DNA approaches for multi-cancer early detection
Summary In the Circulating Cell-free Genome Atlas (NCT02889978) substudy 1, we
evaluate several approaches for a circulating cell-free DNA (cfDNA)-based multi-cancer …
evaluate several approaches for a circulating cell-free DNA (cfDNA)-based multi-cancer …
Limitations and opportunities of technologies for the analysis of cell-free DNA in cancer diagnostics
Cell-free DNA (cfDNA) in the circulating blood plasma of patients with cancer contains
tumour-derived DNA sequences that can serve as biomarkers for guiding therapy, for the …
tumour-derived DNA sequences that can serve as biomarkers for guiding therapy, for the …
[HTML][HTML] Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
MC Liu, GR Oxnard, EA Klein, C Swanton, MV Seiden… - Annals of …, 2020 - Elsevier
Background Early cancer detection could identify tumors at a time when outcomes are
superior and treatment is less morbid. This prospective case-control sub-study (from …
superior and treatment is less morbid. This prospective case-control sub-study (from …
Detecting liquid remnants of solid tumors: circulating tumor DNA minimal residual disease
Growing evidence demonstrates that circulating tumor DNA (ctDNA) minimal residual
disease (MRD) following treatment for solid tumors predicts relapse. These results suggest …
disease (MRD) following treatment for solid tumors predicts relapse. These results suggest …
Minimal residual disease detection using a plasma-only circulating tumor DNA assay in patients with colorectal cancer
AR Parikh, EE Van Seventer, G Siravegna… - Clinical Cancer …, 2021 - AACR
Purpose: Detection of persistent circulating tumor DNA (ctDNA) after curative-intent surgery
can identify patients with minimal residual disease (MRD) who will ultimately recur. Most …
can identify patients with minimal residual disease (MRD) who will ultimately recur. Most …
[HTML][HTML] Cell-free DNA analysis in current cancer clinical trials: a review
M Cisneros-Villanueva, L Hidalgo-Pérez… - British journal of …, 2022 - nature.com
Cell-free DNA (cfDNA) analysis represents a promising method for the diagnosis, treatment
selection and clinical follow-up of cancer patients. Although its general methodological …
selection and clinical follow-up of cancer patients. Although its general methodological …
Current and future perspectives of liquid biopsies in genomics-driven oncology
Precision oncology seeks to leverage molecular information about cancer to improve patient
outcomes. Tissue biopsy samples are widely used to characterize tumours but are limited by …
outcomes. Tissue biopsy samples are widely used to characterize tumours but are limited by …